Friday, March 5, 2021
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Infectious Diseases

Naval Medical Center San Diego Administers Hospital’s First mAb Treatment to COVID-19 Patient

by Global Biodefense Staff
January 30, 2021
Naval Medical Center San Diego Administers Hospital’s First mAb Treatment to COVID-19 Patient

Lt. Cmdr. Raben Talvo, Naval Medical Center San Diego's (NMCSD) Office of Clinical Quality department head, administers the hospital’s first monoclonal antibody (mAb) treatment, bamlanivimab, to a COVID-19-positive patient Jan. 26. Credit: Harley Sarmiento

Naval Medical Center San Diego (NMCSD) administered the hospital’s first monoclonal antibody (mAb) treatment to a COVID-19-positive patient Jan. 26. The intravenous infusion is

Bamlanivimab is approved for emergency use authorization (EUA) guidance from the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in patients 12 years or older with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19.

“The treatment is infused via IV, and [is designed] to decrease or slow down the replication of the virus in the patient,” said Lt. Cmdr. Raben Talvo, NMCSD’s Office of Clinical Quality department head. “We’re preventing the patient’s symptoms from getting worse, thus lessening the strain on our healthcare facility.”

Talvo, a registered nurse, administered the mAb treatment and adhered to the FDA’s high-risk patient guidelines.

“[The treatment] is a one time, one hour infusion plus one hour of observation,” said Talvo. “It’s key for us to identify potential patients who have not only tested positive for COVID-19, but have experienced an onset of symptoms within 10 days before we can offer this treatment. These potential patients would have had mild to moderate symptoms for 10 days or less, and this treatment is not for people who are currently admitted into a hospital due to their symptoms.”

Lt. Cmdr. Alison Lane, NMCSD’s Infectious Diseases division head, said the hospital offers the mAb treatment infusion to all eligible patients, but the decision to proceed is reached via an individualized, shared decision-making process with each patient.
“Getting the mAb treatment to the right patients at the right time to safely maximize potential benefits is logistically challenging,” said Lane.

Capt. Juliann Althoff, NMCSD’s chief medical officer with a background in preventative medicine and a public health physician by trade, said the mAb therapy is currently being administered through local health systems and other military training facilities.
“It’s given as an outpatient infusion with the goal of minimizing severe illness and hospitalizations,” said Althoff. “In addition to the public health essentials of physical distancing and mask-wearing, and the upcoming rollouts of vaccines, [mAb therapy] is an additional option we can now offer our beneficiaries.”

Lane echoed her colleagues’ thoughts that preventing hospital admissions for COVID-19 is not only beneficial to individual patients, but also reduces strain on this hospital and the healthcare system as a whole.

Article adapted from original story by Jacob L. Greenberg, Naval Medical Center San Diego

Tags: COVID CountermeasuresCOVID-19Editor PickMedicine-HealthSARS-CoV-2Therapeutic Antibodies

Related Posts

Medical Countermeasure Development
Funding News

2021 BAA for Development of Medical Countermeasures for Biological Threats

March 2, 2021
UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)
Funding News

UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

March 2, 2021
New Coronavirus Variant: Here Is What Scientists Know About B1525
Biosurveillance

New Coronavirus Variant: Here Is What Scientists Know About B1525

March 2, 2021
How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?
Medical Countermeasures

How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?

March 2, 2021
Load More

Latest News

Medical Countermeasure Development

2021 BAA for Development of Medical Countermeasures for Biological Threats

March 2, 2021
UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

March 2, 2021
New Coronavirus Variant: Here Is What Scientists Know About B1525

New Coronavirus Variant: Here Is What Scientists Know About B1525

March 2, 2021
How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?

How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?

March 2, 2021

Upcoming Events

Mar 5
Virtual Event
March 2 - March 5

Effectiveness of Non-Vaccine Influenza Control Measures

Mar 6
Virtual Event
March 6 - March 10

CROI 2021 – Conference on Retroviruses and Opportunistic Infections

Mar 8
Virtual Event
March 8 - March 10

Quantum-Enabled Sensing and Imaging for Biology

Mar 8
Virtual Event
2:00 pm - 3:30 pm

TRB Webinar: Visualizing Effects of COVID-19 on Transportation: A One-Year Retrospective

Mar 9
Virtual Event
March 9 - March 11

The Current Global Governance Landscape for Influenza

View More
Tweets by GlobalBioD

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2021 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe

© 2021 Stemar Media Group LLC